Novartis, CH0012005267

Novartis stock carries Q2 sales growth into October results

Published on 10/06/2026 at 16:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock was at CHF 117.28 on October 6, 2026, while Q2 sales grew 3 percent in USD. Q3 results are scheduled for October 27.

Futuristisches Forschungsgebäude mit ovaler Glasfassade und Spiegelteich im Vordergrund — Novartis AG CH0012005267 – Futuristisches Forschungsgebäude mit ovaler Glasfassade, Spiegelteich und Grünanlagen, Illustration mit AI erstellt.

Novartis stock was trading at CHF 117.28 on the SIX Swiss Exchange at 3:39 p.m. CEST on October 6, 2026, up 0.69 percent. The company enters the final weeks before its October 27 results with second-quarter sales growth and a reaffirmed full-year outlook.

Q2 sales growth sets the tone

According to Novartis in its July 21, 2026 release, second-quarter net sales grew 1 percent in constant currencies and 3 percent in USD. Core operating income remained flat in both measures, creating a mixed operating picture rather than a broad acceleration.

The product mix was more constructive. Kisqali sales increased 43 percent in the second quarter, according to the same Novartis release, supporting the company's priority-brand strategy as generic competition weighs on mature products.

Pipeline strength meets execution risk

Novartis reaffirmed its full-year 2026 guidance in the July release, calling for low single-digit net sales growth and a low single-digit decline in core operating income in constant currencies. That combination makes the October results important for judging whether newer medicines can offset pricing and generic pressure.

Analyst views remain divided. Barclays analyst James Gordon maintained a Hold rating and set a CHF 130.00 target on October 1, 2026, according to Markets Insider, while Goldman Sachs analyst James Quigley kept a Sell rating with a CHF 110.00 target, also on October 1, 2026, according to Markets Insider.

Stock sits below its yearly high

At CHF 117.28, Novartis stock stood 11.61 percent below its 52-week high of CHF 132.68 and above its 52-week low of CHF 97.05 on October 6, 2026. SIX volume was 841,068 shares, while market capitalization stood at CHF 222.9 billion.

The next numerical checkpoint is the October 27, 2026 Q3 report. Investors will be looking for another period of brand growth and evidence that the reaffirmed guidance remains compatible with flat core operating income in the latest quarter.